Hsp70 Trap Assay for Detection of Misfolded Subproteome Related to Myelodysplastic Syndromes

0518388 - ÚFE 2020 RIV US eng J - Journal Article
Pastva, O. - Chrastinová, L. - Bocková, Markéta - Kotlín, R. - Suttnar, J. - Hlaváčková, A. - Štikarová, J. - Ceznerová, E. - Čermák, J. - Homola, Jiří - Dyr, J. E.
Hsp70 Trap Assay for Detection of Misfolded Subproteome Related to Myelodysplastic Syndromes.
Analytical Chemistry. Roč. 91, č. 22 (2019), s. 14226-14230. ISSN 0003-2700. E-ISSN 1520-6882
R&D Projects: GA ČR(CZ) GBP205/12/G118; GA ČR(CZ) GA19-02739S
Institutional support: RVO:67985882
Keywords : Diagnosis * Proteins
OECD category: Analytical chemistry
Impact factor: 6.785, year: 2019
Method of publishing: Limited access
https://pubs.acs.org/doi/10.1021/acs.analchem.9b04175

The onset and progression of numerous serious diseases (e.g., various types of malignancies, neuro-degenerative diseases, and cardiac diseases) are, on a molecular level, associated with protein modifications and misfolding. Current methods for the detection of misfolded proteins are not able to detect the whole misfolded subproteome and, moreover, are rather laborious and time consuming. Herein, we report on a novel simple method for the detection of misfolded proteins employing a surface plasmon resonance (SPR) biosensor and heat shock protein 70 (Hsp70) that recognizes and traps misfolded proteins in a nucleotide-dependent manner. We use this method for the detection of misfolded proteins in blood plasma of patients with various subtypes of myelodysplastic syndromes (MDS) and healthy donors. Our results reveal significantly elevated levels of misfolded proteins in the two stages of MDS that are most affected by oxidative stress: low-risk (RARS) and intermediate-risk (RCMD) patients. This approach can be extended to a variety of diseases and provides unique insights into the thus far unexplored area of blood proteome.
Permanent Link: http://hdl.handle.net/11104/0303537